Details for Patent: 10,550,098

Which drugs does patent 10,550,098 protect, and when does it expire?

Patent 10,550,098 protects REZLIDHIA and is included in one NDA.

This patent has eighty-seven patent family members in thirty-six countries.

Summary for Patent: 10,550,098

Patent landscape, scope, and claims:

Title:	Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
Abstract:	The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula:
Inventor(s):	Lin Jian, Ericsson Anna, Campbell Ann-Marie, Gustafson Gary, Wang Zhongguo, Diebold R. Bruce, Ashwell Susan, Lancia, Jr. David R., Caravella Justin Andrew, Lu Wei
Assignee:	Forma Therapeutics, Inc.
Application Number:	US16290240
Patent Claim Types: see list of patent claims

Drugs Protected by US Patent 10,550,098

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Rigel Pharms	REZLIDHIA	olutasidenib	CAPSULE;ORAL	215814-001	Dec 1, 2022		RX	Yes	Yes	10,550,098		Y

International Family Members for US Patent 10,550,098

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	101976
Australia	2015317322
Australia	2015317327